Untargeted high-resolution metabolomic analysis of stool revealed that CDI is associated with a distinct fecal metabolic milieu mapping to 14 significantly dysregulated pathways that may promote inflammation, impair colonization resistance, and facilitate C. difficile replication.
Key Findings
Results
CDI stool exhibited marked alterations in fecal metabolites mapping to 14 significantly dysregulated metabolic pathways compared to healthy controls.
Study compared stool from 55 CDI patients and 72 healthy controls using untargeted high-resolution metabolomics (HRM).
Dysregulated pathways included tryptophan metabolism, bile acid metabolism, short-chain fatty acid metabolism, and fatty acid oxidation.
The approach was untargeted, allowing discovery of metabolites without prior hypothesis about specific compounds.
CDI was described as associated with 'marked alterations in stool metabolites.'
Results
Bile acid metabolism was among the most significantly dysregulated pathways in CDI stool compared to healthy controls.
Bile acid biosynthesis pathways were identified as strongly correlating with disease state.
Disruption of bile acid metabolism is consistent with known mechanisms by which microbiome disruption facilitates C. difficile colonization.
Bile acid alterations were identified as potential biomarkers distinguishing CDI from healthy stool.
The findings corroborate previous studies on bile acid dysregulation in CDI.
Results
Tryptophan metabolism was identified as a significantly dysregulated pathway in CDI, with implications for immune and microbial signaling.
Tryptophan metabolism was listed among the 14 dysregulated pathways associated with CDI.
Authors suggest findings support further investigation of microbial and immune signaling roles in CDI.
Tryptophan metabolism was noted as correlating with disease in the stool metabolome.
The pathway was identified using untargeted HRM on stool samples from 55 CDI patients and 72 healthy controls.
Results
Short-chain fatty acid (SCFA) metabolism and fatty acid oxidation pathways were significantly dysregulated in CDI stool.
Both SCFA metabolism and fatty acid oxidation were among the 14 significantly dysregulated pathways identified.
SCFA disruption may relate to impaired colonization resistance in CDI.
Carnitine activation, involved in fatty acid transport and oxidation, was identified as more associated with healthy stool.
These findings suggest CDI alters host and microbial energy metabolism in the gut.
Discussion
The fecal metabolic profile of CDI may promote inflammation, impair colonization resistance, and facilitate C. difficile replication.
Authors describe CDI as associated with 'a distinct fecal metabolic milieu that may promote inflammation, impair colonization resistance, and facilitate C. difficile replication.'
Findings were interpreted in the context of gut microbiome disruption, typically precipitated by antimicrobial use.
Results support the concept that metabolic disturbances, not just microbial composition changes, contribute to CDI pathophysiology.
The study design included 55 CDI patients and 72 healthy controls to characterize this metabolic phenotype.
Results
Certain metabolic pathways, including bile acid biosynthesis, tryptophan metabolism, and carnitine activation, were more associated with healthy stool than CDI stool.
The authors identified chemical pathways 'more associated with healthy stool' as a distinct finding from those dysregulated in disease.
Bile acid biosynthesis, tryptophan metabolism, and carnitine activation were specifically named as more prevalent in healthy controls.
This bidirectional metabolomic comparison helps identify both loss-of-health markers and gain-of-disease markers.
Healthy controls numbered 72, compared to 55 CDI patients.
Background
Untargeted high-resolution metabolomics identified expanded biomarkers of CDI beyond those found in prior targeted studies.
The authors note that 'fewer have explored the fecal metabolome using untargeted high-resolution metabolomics (HRM),' positioning this as a methodological advancement over prior work.
Untargeted HRM allows detection of metabolites without prior hypothesis, enabling discovery of novel biomarkers.
Results support 'further investigation of metabolic biomarkers and therapeutic targets' for CDI.
The study design used stool samples from 55 CDI patients and 72 healthy controls.
What This Means
This research suggests that Clostridioides difficile infection (CDI)—a serious gut infection often triggered by antibiotic use—leaves a distinct chemical fingerprint in stool that differs markedly from healthy individuals. By using an advanced, hypothesis-free laboratory technique called high-resolution metabolomics, the researchers analyzed stool samples from 55 people with CDI and 72 healthy people, identifying 14 metabolic pathways that were significantly altered in the infected group. Key disrupted pathways included those involved in bile acids (which help regulate gut bacteria), tryptophan (an amino acid linked to immune function), short-chain fatty acids (important for gut health), and fat metabolism.
The findings help explain why CDI is so difficult for the body to fight off: the chemical environment in an infected gut appears to simultaneously reduce the gut's natural defenses (colonization resistance), promote inflammation, and create conditions favorable for C. difficile to grow. Notably, some of these metabolic features—like bile acid biosynthesis, tryptophan metabolism, and carnitine activation—were more characteristic of healthy stool, suggesting these may represent protective factors that are lost during infection.
This research suggests that stool metabolites could serve as improved diagnostic biomarkers for CDI and may point toward new treatment targets. Rather than focusing solely on which bacteria are present, examining the chemical products those bacteria produce (and fail to produce) may offer a more complete picture of disease. The authors note their results are consistent with prior studies and support further investigation into how metabolic and immune signals interact during C. difficile infection.
Mehta N, Guzzetta V, Liu K, Webster A, Adelman M, Fitts E, et al.. (2026). High-resolution metabolomic analysis of stool reveals expanded biomarkers of C. difficile colitis and insights into pathophysiology.. Microbiology spectrum. https://doi.org/10.1128/spectrum.02826-25